Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Slides:



Advertisements
Similar presentations
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Striking leflunomide efficacy against refractory cutaneous sarcoidosis
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Efficacy of simvastatin in plaque psoriasis: A pilot study
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis  Lorinda Chung, MD, David Fiorentino,
Pilot study of a skin cancer education curriculum for medical students
Amy S. Paller, MD, Elaine C. Siegfried, MD, David M
Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection  Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.
Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry  Bruce Strober,
Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale  Vanessa Lindsay Pascoe, MD, Alexandra Boer.
A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies  Linda.
Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study 
A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening  Dayoung Ko, BS, Shari R. Lipner, MD, PhD 
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.
Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks
Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,
Lip edema Journal of the American Academy of Dermatology
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.
Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions  Herbert C. Chiang, MD,
Appearance of lentigines in psoriasis patients treated with apremilast
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.
Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity  David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.
Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial  Sonja Ständer, MD, Paul Kwon, MD,
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.
Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L
Modification of the nail psoriasis severity index
Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.
Tofacitinib therapy for children with severe alopecia areata
Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial  Boni E. Elewski, MD, Martin.
Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.
An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis  James Krell, MD, FAAD, Candi Nelson, BS,
Gaps in pain management in dermatology: A needs assessment from Canada
Alan Menter, MD, Stephen K
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-
Efficacy and safety of oxymetazoline cream 1
Brittany G. Craiglow, MD, Brett A. King, MD, PhD 
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne  Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,
Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani  Erwin Suys, MD  Journal of the American Academy.
“Boot foot” with pseudomonas colonization
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.
Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals  Cynthia Haddad, PharmD, MSc, Odette Berline.
Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment  Michael.
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.
Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial  Diane Thiboutot, MD, David.
Presentation transcript:

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials  Linda Stein Gold, MD, Mark G. Lebwohl, MD, Jeffrey L. Sugarman, MD, PhD, David M. Pariser, MD, Tina Lin, PharmD, Gina Martin, MOT, Radhakrishnan Pillai, PhD, Robert Israel, MD, Tage Ramakrishna, MD  Journal of the American Academy of Dermatology  Volume 79, Issue 2, Pages 287-293 (August 2018) DOI: 10.1016/j.jaad.2018.03.040 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Summary of subject disposition in the 2 phase 3 studies (all randomized patients [N = 418]). HP/TAZ, Halobetasol propionate plus tazarotene. Journal of the American Academy of Dermatology 2018 79, 287-293DOI: (10.1016/j.jaad.2018.03.040) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Investigator's Global Assessment (IGA) score for disease severity at each study visit. Subjects were categorized as treatment successes (defined as at least a 2-grade improvement from the baseline score and a score of clear or almost clear) (individual study data for the intent-to-treat population). HP/TAZ, Halobetasol propionate plus tazarotene. Journal of the American Academy of Dermatology 2018 79, 287-293DOI: (10.1016/j.jaad.2018.03.040) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Improvement in signs of psoriasis—erythema, plaque elevation, and scaling—at each study visit in subjects who were treatment successes (defined as at least a 2-grade improvement from the baseline score) (individual study data for the intent-to-treat population). HP/TAZ, Halobetasol propionate plus tazarotene. Journal of the American Academy of Dermatology 2018 79, 287-293DOI: (10.1016/j.jaad.2018.03.040) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Reduction in local skin reactions at each study visit (pooled study data for the safety population). HP/TAZ, Halobetasol propionate plus tazarotene. Journal of the American Academy of Dermatology 2018 79, 287-293DOI: (10.1016/j.jaad.2018.03.040) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions